Core One Labs Revenue

In the fiscal year ending March 31, 2023, Core One Labs had annual revenue of 458.54K CAD, down -29.25%. Core One Labs had revenue of 93.66K in the quarter ending December 31, 2023, a decrease of -17.22%.

Revenue

458.54K CAD

Revenue Growth

-18.65%

P/S Ratio

14.68

Revenue / Employee

n/a

Employees

n/a

Market Cap

4.97M USD

Revenue Chart

* This company reports financials in CAD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2023	458.54K	-189.55K	-29.25%
Dec 31, 2022	648.09K	216.47K	50.15%
Dec 31, 2021	431.62K	-	-
Dec 31, 2020	-	-	-
Dec 31, 2019	-	-	-
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro
Dec 31, 2014	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Endo, Inc.	1.73B
Veradigm	588.02M
Elite Pharmaceuticals	70.00M
Tian'an Technology Group	1.78M
American Oncology Network	1.76B
Glass House Brands	215.62M
Northwest Biotherapeutics	1.47M
Silence Therapeutics	27.70M

Revenue Rankings

Core One Labs News

1 year ago - Core One Enters into Loan Agreement with Right Season Investments - Accesswire
1 year ago - Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market - Accesswire
1 year ago - Core One Labs' Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods - Accesswire
2 years ago - Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease - Accesswire
2 years ago - Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass - Accesswire
2 years ago - Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease - Accesswire
2 years ago - Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds - Accesswire
2 years ago - Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin - Accesswire

More News